Thrombolytic therapy for acute ischemic stroke

Journal of the Neurological Sciences

Volumn 261, Issue 1-2, 2007, Pages 55-62

  Blakeley, Jaishri O ^a   Llinas, Rafael H ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Acute ischemic stroke; Intra arterial thrombolysis; Revascularization; rt PA; Thrombolytic therapy

Indexed keywords

ALTEPLASE; DESMOTEPLASE; EPTIFIBATIDE; FIBRINOLYTIC AGENT; HEPARIN; PLACEBO; PROUROKINASE; STREPTOKINASE; TENECTEPLASE; UROKINASE;

ACUTE DISEASE; ARTERY OCCLUSION; ARTICLE; BASILAR ARTERY; BLEEDING; BLOOD CLOT LYSIS; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; CONTINUOUS INFUSION; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG FATALITY; DRUG MEGADOSE; FIBRINOLYTIC THERAPY; FOOD AND DRUG ADMINISTRATION; HEART DISEASE; HUMAN; LOW DRUG DOSE; MONOTHERAPY; MORBIDITY; MORTALITY; NUCLEAR MAGNETIC RESONANCE IMAGING; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PRIORITY JOURNAL; ULTRASOUND;

ACUTE DISEASE; ANGIOPLASTY; ANTICOAGULANTS; BASILAR ARTERY; CEREBROVASCULAR ACCIDENT; CLINICAL TRIALS; CLINICAL TRIALS, PHASE IV; HUMANS; INFUSIONS, INTRAVENOUS; ISCHEMIA; STREPTOKINASE; THROMBOLYTIC THERAPY; TISSUE PLASMINOGEN ACTIVATOR; ULTRASONOGRAPHY, DOPPLER, TRANSCRANIAL;

EID: 34548179532     PISSN: 0022510X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jns.2007.04.031     Document Type: Article

References (42)

1. Bruno A., Levine S.R., Frankel M.R., Brott T.G., Lin Y., Tilley B.C., et al., NINDS rt-PA Stroke Study Group. Admission glucose level and clinical outcomes in the NINDS rt-PA Stroke Trial. Neurology 10;59 5 (2002) 669-674
2. International Society of Hypertension (ISH). Statement on the management of blood pressure in acute stroke. J Hypertens 21 (2003) 665-672
3. Schwarz S., Georgiadis D., Aschoff A., and Schwab S. Effects of induced hypertension on intracranial pressure and flow velocities of the middle cerebral arteries in patients with large hemispheric stroke. Stroke 33 (2002) 998-1004
4. Kasner S.E., Wein T.H., Piriyawat P., Villar-Cordova C.E., Chalela J.A., Krieger D.W., et al. Acetaminophen for altering body temperature in acute stroke. Stroke 33 (2002) 130-134
5. Randomised controlled trial of streptokinase, aspirin, and combination of both in treatment of acute ischemic stroke. Multicentre Acute Stroke Trial-Italy Group. Lancet 346 (1995) 1509-1514
6. Hacke W., Kaste M., Fieschi C., Toni D., Lesaffre E., von Kummer R., et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS). JAMA 274 (1995) 1017-1025 [see comments]
7. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke t-PA Stroke Study Group. N Engl J Med 333 (1995) 1581-1587 [see comments]
8. Thrombolytic therapy with streptokinase in acute ischemic stroke. The Multicenter Acute Stroke Trial-Europe Study Group. NEJM 335 (1996) 145-150
9. Donnan G.A., Davis S.M., Chambers B.R., Gates P.C., Hankey G.J., McNeil J.J., et al. Streptokinase for acute ischemic stroke with relationship to time of administration: Australian Streptokinase Trial Study Group. JAMA 276 (1996) 961-966
10. Hacke W., Kaste M., Fieschi C., von Kummer R., Davalos A., Meier D., et al. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischemic stroke (ECASS II). Second European-Australian Acute Stroke Study Investigators. Lancet 352 (1998) 1245-1251 [see comments]
11. Clark WM, Wissman S, Albers GW, Jhamandas JH, Madden KP, Hamilton S, et al. Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 h after symptom onset. The ATLANTIS Study: a randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke. JAMA 282; 2019-2026, 1999.
12. The NINDS t-PA Stroke Study Group. Generalized efficacy of t-PA for acute ischemic stroke. Subgroup analysis of the NINDS t-PA Stroke Trial. Stroke 28 (1997) 2119-2125
13. Kwiatkowski T.G., Libman R.B., Frankel M., Tilley B.C., Morgenstern L.B., Lu M., et al. Effects of tissue-plasminogen activator for acute ischemic stroke at one year. National Institute of Neurological Disorders and Stroke Recombinant Tissue Plasminogen Activator Stroke Study Group. N Engl J Med 340 (1999) 1781-1787 [see comments]
14. Albers G.W., Bates V.E., Clark W.M., Bell R., Verro P., and Hamilton S.A. Intravenous tissue-type plasminogen activator for treatment of acute stroke: the Standard Treatment with Alteplase to reverse Stroke (STARS) study. JAMA 283 (2000) 1145-1150 [see comments]
15. Chiu D., Krieger D., Villar-Cordova C., Kasner S.E., Morgenstern L.B., Bratina P.L., et al. Intravenous tissue plasminogen activator for acute ischemic stroke: feasibility, safety, and efficacy in the first year of clinical practice. Stroke 29 1 (1998) 18-22
16. Tanne D., Bates V.E., Verro P., Kasner S.E., Binder J.R., Patel S.C., et al. Initial clinical experience with IV tissue plasminogen activator for acute ischemic stroke: a multicenter survey. The t-PA Stroke Survey Group. Neurology 53 (1999) 424-427
17. Grotta J.C., Burgin W.S., El-Mitwalli A., Long M., Campbell M., Morgenstern L.B., et al. Intravenous tissue-type plasminogen activator therapy for ischemic stroke: Houston experience 1996 to 2000. Arch Neurol 58 12 (2001) 2009-2013
18. Katzan I.L., Furlan A.J., Lloyd L.E., Frank J.I., Harper D.L., Hinchey J.A., et al. Use of tissue-type plasminogen activator for acute ischemic stroke: the Cleveland area experience. JAMA 283 (2000) 1151-1158
19. Katzan I.L., Hammer M.D., Furlan A.J., Hixson E.D., Nadzam D.M., and Cleveland Clinic Health System Stroke Quality Improvement Team. Quality improvement and tissue-type plasminogen activator for acute ischemic stroke: a Cleveland update. Stroke 34 (2003) 799-800
20. Lopez-Yunez A.M., Bruno A., Williams L.S., Yilmaz E., Zurru C., and Biller J. Protocol violations in community-based rTPA stroke treatment are associated with symptomatic intracerebral hemorrhage. Stroke 32 1 (2001) 12-16
21. Hacke W., Albers G., Al-Rawi Y., Bogousslavsky J., Davalos A., Eliasziw M., et al. The desmoteplase in acute ischemic stroke trial (DIAS). A phase II MRI-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase. Stroke 36 (2005) 66-73
22. CLOTBUST Investigators. Ultrasound-enhanced thrombolysis for acute ischemic stroke: phase I. Findings of the CLOTBUSTtrial. J Neuroimaging 14 2 (Apr 2004) 113-117
23. CLOTBUST Investigators. Ultrasound-enhanced systemic thrombolysis for acute ischemic stroke. N Engl J Med 351 21 (Nov 18 2004) 2154-2155
24. TNK in Stroke Investigators. A pilot dose-escalation safety study of tenecteplase in acute ischemic stroke. Stroke 36 3 (Mar 2005) 607-612
25. del Zoppo G.J., Higashida R.T., Furlan A.J., Pessin M.S., Rowley H.A., and Gent M. PROACT: a phase II randomized trial of recombinant pro-urokinase by direct arterial delivery in acute middle cerebral artery stroke. PROACT Investigators. Prolyse in acute cerebral thromboembolism. [see comments]. Stroke 29 (1998) 4-11
26. Furlan A., Higashida R., Wechsler L., Gent M., Rowley H., Kase C., et al. Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: a randomized controlled trial. Prolyse in acute cerebral thromboembolism. JAMA 282 21 (1999) 2003-2011
27. Jahan R., Duckwiler G.R., Kidwell C.S., Sayre J.W., Gobin Y.P., Villablanca J.P., et al. Intraarterial thrombolysis for treatment of acute stroke: experience of 26 patients with long-term follow-up. AJNR Am J Neuroradiol 20 (1999) 1291-1299
28. Gonner F., Remonda L., Mattle H., Sturzenegger M., Ozdoba C., Lovblad K.O., et al. Local intra-arterial thrombolysis in acute ischemic stroke. Stroke 29 (1998) 1894-1900
29. Suarez J.I., Sunshine J.L., Tarr R., Zaidat O., Selman W.R., Kernich C., et al. Predictors of clinical improvement, angiographic recanalization, and intracranial hemorrhage after intra-arterial thrombolysis for acute ischemic stroke. Stroke 30 10 (1999) 2094-2100
30. Lewandowski C.A., Frankel M., Tomsick T.A., Broderick J., Frey J., Clark W., et al. Combined intravenous and intra-arterial r-TPA versus intra-arterial therapy of acute ischemic stroke. Emergency Management of Stroke (EMS) Bridging Trial. Stroke 30 (1999) 2598-2605
31. Ernst R., Pancioli A., Tomsick T., Kissela B., Woo D., Kanter D., et al. Combined intravenous and intra-arterial recombinant tissue plasminogen activator in acute ischemic stroke. Stroke 31 (2000) 2552-2557
32. Suarez J.I., Zaidat O.O., Sunshine J.L., Tarr R., Selman W.R., and Landis D.M. Endovascular administration after intravenous infusion of thrombolytic agents for the treatment of patients with acute ischemic strokes. Neurosurgery 50 2 (2002) 251-259
33. Nakano S., Yokogami K., Ohta H., Yano T., and Ohnishi T. Direct percutaneous transluminal angioplasty for acute middle cerebral artery occlusion. AJNR Am J Neuroradiol 19 (1998) 767-772
34. Nakano S., Iseda T., Yoneyama T., Kawano H., and Wakisaka S. Direct percutaneous transluminal angioplasty for acute middle cerebral artery trunk occlusion: an alternative option to intra-arterial thrombolysis. Stroke 33 12 (2002) 2872-2876
35. Yoneyama T., Nakano S., Kawano H., Iseda T., Ikeda T., Goya T., et al. Combined direst percutaneous transluminal angioplasty with low-dose native tissue plasminogen activator therapy for acute embolic middle cerebral artery trunk occlusion. AJNR Am J Neuroradiol 23 (2002) 277-281
36. Pierre Gobin Y., Starkman S., Duckwiler G.R., Grobelny T., Kidwell C.S., Jahan R., et al. MERCI 1: A Phase 1 Study of Mechanical Embolus Removal in Cerebral Ischemia Stroke vol. 35 (2004) 2848-2854
37. Qureshi A.I., Siddiqui A.M., Suri M.F., Kim S.H., Ali Z., Yahia A.M., et al. Aggressive mechanical clot disruption and low-dose intra-arterial third-generation thrombolytic agent for ischemic stroke: a prospective study. Neurosurgery 51 (2002) 1319-1327
38. Hacke W., Zeumer H., Ferbert A., Bruckmann H., and del Zoppo G.J. Intra-arterial thrombolytic therapy improves outcome in patients with acute vertebrobasilar occlusive disease. Stroke 19 (1988) 1216-1222
39. Becker K.J., Monsein L.H., Ulatowski J., Mirski M., Williams M., and Hanley D.F. Intraarterial thrombolysis in vertebrobasilar occlusion. AJNR Am J Neuroradiol 17 (1996) 255-262
40. Wijdicks E.F., Nichols D.A., Thielen K.R., Fulgham J.R., Brown Jr. R.D., Meissner I., et al. Intra-arterial thrombolysis in acute basilar artery thromboembolism: the initial Mayo Clinic experience. Mayo Clin Proc 72 (1997) 1005-10013
41. Grond M., Rudolf J., Schmulling S., Stenzel C., Neveling M., and Heiss W.D. Early intravenous thrombolysis with recombinant tissue-type plasminogen activator in vertebrobasilar ischemic stroke. Arch Neurol 55 (1998) 466-469
42. Cross D.T., Derdeyn C.P., and Moran C.J. Bleeding complications after basilar artery fibrinolysis with tissue plasminogen activator. AJNR Am J Neuroradiol 22 (2001) 521-525